ReviewTherapeutic advances in endocrinology and metabolism2019
Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review.
Review in Therapeutic advances in endocrinology and metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Cost-effectiveness of cabozantinib versus placebo for advanced neuroendocrine tumors from crossover-adjusted analysis in the United States and China.Scientific reports · 2026Article
- Predictors of All-Cause In-Hospital Mortality in Patients With Malignant Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.World journal of oncology · 2025Article
- Factors Influencing Costs of Cancer Care for Patients with Neuroendocrine Neoplasms.Neuroendocrinology · 2025Review
- Computing the Cost of Care per Patient per Day for Patients With Metastatic Neuroendocrine Neoplasms.JCO oncology practice · 2024Article
- Evaluating cost-effectiveness in the management of neuroendocrine neoplasms.Reviews in endocrine & metabolic disorders · 2021Review
- Cost-Effectiveness Analysis ofDiagnostics (Basel, Switzerland) · 2021Article
- The Economic Impact on Australian Patients with Neuroendocrine Tumours.The patient · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses. Compounding the issue is that data on resource utilization and cost-effectiveness of different diagnostic and therapeutic modalities for GEP-NETs are scarce.
methodsA systematic review on the economic impact of GEP-NETs was carried out using four databases:
resultsThe 14 studies selected included cost-of-illness analyses (
conclusionThere is a lack of data related to resource utilization in the field of GEP-NETs. Therefore, cost-effectiveness and budget impact studies of existing and emerging treatments are urgently needed to help the decision-making process for patients with NETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.